JP2006511585A - 慢性創傷管理における活性酸素種の減少 - Google Patents
慢性創傷管理における活性酸素種の減少 Download PDFInfo
- Publication number
- JP2006511585A JP2006511585A JP2004563981A JP2004563981A JP2006511585A JP 2006511585 A JP2006511585 A JP 2006511585A JP 2004563981 A JP2004563981 A JP 2004563981A JP 2004563981 A JP2004563981 A JP 2004563981A JP 2006511585 A JP2006511585 A JP 2006511585A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- wound
- ions
- parts
- ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 43
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 43
- 239000003642 reactive oxygen metabolite Substances 0.000 title claims abstract description 26
- 230000001684 chronic effect Effects 0.000 title abstract description 11
- 230000009467 reduction Effects 0.000 title description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 36
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 229910001419 rubidium ion Inorganic materials 0.000 claims abstract description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 6
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 6
- 229910001414 potassium ion Inorganic materials 0.000 claims abstract description 6
- 210000003622 mature neutrocyte Anatomy 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 9
- -1 superoxide anions Chemical class 0.000 claims description 7
- 230000029663 wound healing Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 239000005667 attractant Substances 0.000 claims 1
- 230000031902 chemoattractant activity Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 230000024203 complement activation Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 238000003556 assay Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 239000000523 sample Substances 0.000 description 8
- 108010093894 Xanthine oxidase Proteins 0.000 description 7
- 239000013256 coordination polymer Substances 0.000 description 7
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 6
- 241000219492 Quercus Species 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229920000392 Zymosan Polymers 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229960002319 barbital Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WPUZGNPQMIWOHE-UHFFFAOYSA-N 3',6'-diacetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid Chemical compound O1C(=O)C2=CC(C(O)=O)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 WPUZGNPQMIWOHE-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102000004722 NADPH Oxidases Human genes 0.000 description 2
- 108010002998 NADPH Oxidases Proteins 0.000 description 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43619702P | 2002-12-23 | 2002-12-23 | |
| PCT/US2003/041038 WO2004057965A1 (en) | 2002-12-23 | 2003-12-23 | Reduction of reactive oxygen species in chronic wound management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006511585A true JP2006511585A (ja) | 2006-04-06 |
| JP2006511585A5 JP2006511585A5 (cg-RX-API-DMAC7.html) | 2007-02-15 |
Family
ID=32682357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563981A Pending JP2006511585A (ja) | 2002-12-23 | 2003-12-23 | 慢性創傷管理における活性酸素種の減少 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1575359A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006511585A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1744819A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003303335A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2511440A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004057965A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016028050A (ja) * | 2008-04-01 | 2016-02-25 | アントイポデアン ファーマシューティカルズ, インコーポレイテッド | スキンケア用組成物及び方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011022757A1 (en) * | 2009-08-24 | 2011-03-03 | Queensland University Of Technology | Purine-targeted diagnosis and therapy of wounds |
| WO2013016255A1 (en) * | 2011-07-28 | 2013-01-31 | 3M Innovative Properties Company | Wound-healing compositions and method of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60239421A (ja) * | 1984-05-07 | 1985-11-28 | ゲデツケ アクチエンゲゼルシヤフト | 創傷の肉芽および上皮形成を促進させるための局所性調合薬 |
| JPH08503462A (ja) * | 1992-11-06 | 1996-04-16 | エイチ・イー・スタンリー・ファーマシューティカルズ・インコーポレイテッド | オーク樹皮抽出物の組成物、関連する合成組成物およびこれを用いる方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ533252A (en) * | 2001-11-29 | 2006-03-31 | Greystone Medical Group Inc | Treatment of wounds and compositions employed |
-
2003
- 2003-12-23 WO PCT/US2003/041038 patent/WO2004057965A1/en not_active Ceased
- 2003-12-23 JP JP2004563981A patent/JP2006511585A/ja active Pending
- 2003-12-23 EP EP03808544A patent/EP1575359A4/en not_active Withdrawn
- 2003-12-23 CA CA002511440A patent/CA2511440A1/en not_active Abandoned
- 2003-12-23 AU AU2003303335A patent/AU2003303335A1/en not_active Abandoned
- 2003-12-23 CN CNA2003801095668A patent/CN1744819A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60239421A (ja) * | 1984-05-07 | 1985-11-28 | ゲデツケ アクチエンゲゼルシヤフト | 創傷の肉芽および上皮形成を促進させるための局所性調合薬 |
| JPH08503462A (ja) * | 1992-11-06 | 1996-04-16 | エイチ・イー・スタンリー・ファーマシューティカルズ・インコーポレイテッド | オーク樹皮抽出物の組成物、関連する合成組成物およびこれを用いる方法 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6010028783, 医薬品添加物事典, 1994, 第1版, p.355, 株式会社薬事日報社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016028050A (ja) * | 2008-04-01 | 2016-02-25 | アントイポデアン ファーマシューティカルズ, インコーポレイテッド | スキンケア用組成物及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1575359A4 (en) | 2009-08-05 |
| CN1744819A (zh) | 2006-03-08 |
| EP1575359A1 (en) | 2005-09-21 |
| AU2003303335A1 (en) | 2004-07-22 |
| CA2511440A1 (en) | 2004-07-15 |
| WO2004057965A1 (en) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080220091A1 (en) | Reduction of reactive oxygen species in chronic wound management | |
| Erel et al. | Oxidative stress of platelets and thrombocytopenia in patients with vivax malaria | |
| Venturini et al. | Synthesis of nitric oxide in the bovine retina | |
| Liu et al. | Sulforaphane can protect lens cells against oxidative stress: implications for cataract prevention | |
| Lachance et al. | Stattic V, a STAT3 inhibitor, affects human spermatozoa through regulation of mitochondrial activity | |
| Pizzurro et al. | Diazinon and diazoxon impair the ability of astrocytes to foster neurite outgrowth in primary hippocampal neurons | |
| Engel et al. | What happens to the unsuccessful spermatozoa? | |
| Burden et al. | Investigation into the structural integrity of lysosomes in the normal and dystrophic rat retina | |
| Abubakar et al. | Regional accumulation of aluminium in the rat brain is affected by dietary vitamin E | |
| EP0070992B1 (de) | Verfahren zur Stabilisierung von Peroxidase in einem flüssigen Medium und so stabilisiertes Medium | |
| Kim et al. | Effect of select antioxidants on malondialdehyde modification of proteins | |
| Gamaley et al. | Activation of murine macrophages by hydrogen peroxide | |
| Landmann et al. | Irreversible synthetische inhibitoren der Urokinase | |
| Haenen et al. | Contribution of 4-hydroxy-2, 3-trans-nonenal to the reduction of β-adrenoceptor function in the heart by oxidative stress | |
| AU2003303335A1 (en) | Reduction of reactive oxygen species in chronic wound management | |
| DK1115697T3 (da) | Umættede hydroximsyrederivater som PARP-inhibitorer | |
| Esteve et al. | BRCA1 negatively regulates formation of autophagic vacuoles in MCF-7 breast cancer cells | |
| Van der Zee et al. | The influence of ozone on human red blood cells. Comparison with other mechanisms of oxidative stress | |
| US5578300A (en) | Treatment of allergic contact dermatitis | |
| Morawetz et al. | The effect of poly (acrylic acid) on the tryptic digestion of hemoglobin | |
| Siddiqui et al. | Balamuthia mandrillaris: role of galactose in encystment and identification of potential inhibitory targets | |
| BR112021024414A2 (pt) | Composição para manter ou melhorar a qualidade da carne processada, método para a preparação de uma composição para manter ou melhorar a qualidade da carne processada e processo para preparar carne processada | |
| NO20044503L (no) | Fremgangsmate for a inhihere celle vekst ved anvendelse av oligonukleotider | |
| Okabe et al. | Free radical damage to sarcoplasmic reticulum of masseter muscle by arachidonic acid and prostaglandin G2 | |
| Nishida et al. | Teprenone, an anti-ulcer agent, increases gastric mucosal mucus level via nitric oxide in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100601 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101026 |